Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: A comparative analysis. A phase II trial of anlotinib and fulvestrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback